ERADICATECANNABICS™ RCC-33Drug candidate for the treatmentof Colorectal Cancer (CRC)

COLORECTAL CANCER (CRC)

• 3rd most commonly diagnosed cancer worldwide

• 1,849,518 new cases in 2018 worldwide

• 2nd most lethal cancer worldwide

• 880,792 deaths in 2018 worldwide

• 67% of treated patients survive 5 years or more

CLINICAL PATH

• Preclinical POC validation (ongoing)

• Dossier preparation for submission of Pre-IND meeting request with FDA

SYNERGISTIC INTERACTION OF RCC-33 ON COLON CANCER CELL LINES

RCC-33: >70% dead cancer cells

CANNABICS™ RCC-33 DRUG CANDIDATE FOR TREATING COLON CANCER

• A novel cannabinoid-based formulation

• Formula demonstrated significant synergistic antitumor effect in pre clinical studies

• No psychoactive effect

• Patent pending